A Novel Chemotherapy Combination to Enhance Proteotoxic Cell Death in Hepatocellular Carcinoma Experimental Models Without Killing Non-Cancer Cells
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26146699 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Carlos Perez-Stable und 7 weiteren Autor:innen. Beteiligte Einrichtung: Research Service, Bruce W. Carter Veterans Affairs Medical Center, Miami, FL 33125, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Boron Compounds, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, NIH HHS, Bankhead-Coley Cancer Research Program (State of Florida).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Inhibitors of the ubiquitin–proteasome system increase proteotoxic stress and have achieved clinical success for multiple myeloma but not for solid cancers such as hepatocellular carcinoma. Our objective is to identify a combination with proteasome inhibitors that enhances proteotoxic stress and apoptotic cell death in hepatocellular carcinoma but with less toxicity to non-cancer cells. We found that rencofilstat, a pan-cyclophilin inhibitor, combined with ixazomib, a proteasome inhibitor, increased apoptotic cell death in hepatocellular carcinoma but not in umbilical vein or dermal fibroblast non-cancer cells. We then analyzed the effects of rencofilstat + ixazomib on XBP1s and PERK, critical factors in the unfolded protein response used by cells to survive proteotoxic stress. Rencofilstat + ixazomib maintained higher expression of XBP1s and genetic models suggested that XBP1s was a pro-survival protein early and pro-death protein at later times. Simultaneously, decreased PERK expression prevented the block in protein synthesis via phospho-eIF2α and likely further amplified proteotoxic stress. Rencofilstat + ixazomib did not have effects on XBP1s or PERK in non-cancer cells. Further genetic experiments revealed the pro-survival roles for cyclophilin A and B in mediating rencofilstat + ixazomib-induced cell death. In the Hep3B xenograft model, rencofilstat + ixazomib significantly inhibited tumor volumes/weights without general toxicity. We conclude that rencofilstat + ixazomib amplified proteotoxic stress in hepatocellular carcinoma past a threshold pro-survival pathways could not tolerate, whereas non-cancer cells were less affected.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Service, Bruce W. Carter Veterans Affairs Medical Center, Miami, FL 33125, USA.
- South Florida VA Foundation for Research and Education, Miami, FL 33125, USA.
- Geriatric Research, Education, and Clinical Center, Bruce W. Carter Veterans Affairs Medical Center, Miami, FL 33125, USA.
- Department of Medicine, Division of Gerontology & Palliative Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
- Hepion Pharmaceuticals, Edmonton, AB T5J 4P6, Canada.
ORCID-Profile: Manojavan Nagarajan, Robert T Foster, Medhi Wangpaichitr
Förderung
- BLRD VA
- NIH HHS
- Bankhead-Coley Cancer Research Program (State of Florida)
- Veterans Affairs BLR&D Distinguished Medical Research Scientist Award
- NIH
- Bankhead–Coley Cancer Research Program
- Veterans Affairs BLR&D Distinguished Medical Research Scientist Award
- Miami VA Geriatric Research and Clinical Center (GRECC)
Zitieren
APA
Perez-Stable, C., de Las Pozas, A., Reiner, T., Gomez, J., Nagarajan, M., Foster, R. T., Ure, D. R., & Wangpaichitr, M. (2025). A Novel Chemotherapy Combination to Enhance Proteotoxic Cell Death in Hepatocellular Carcinoma Experimental Models Without Killing Non-Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26146699
Vancouver
Perez-Stable C, de Las Pozas A, Reiner T, Gomez J, Nagarajan M, Foster RT, et al. A Novel Chemotherapy Combination to Enhance Proteotoxic Cell Death in Hepatocellular Carcinoma Experimental Models Without Killing Non-Cancer Cells. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26146699
BibTeX
@article{PerezStable2025,
author = {Perez-Stable, Carlos and de Las Pozas, Alicia and Reiner, Teresita and Gomez, Jose and Nagarajan, Manojavan and Foster, Robert T and Ure, Daren R and Wangpaichitr, Medhi},
title = {A Novel Chemotherapy Combination to Enhance Proteotoxic Cell Death in Hepatocellular Carcinoma Experimental Models Without Killing Non-Cancer Cells},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26146699}
}
EUVIMED